US2014113922A1PendingUtilityA1

Compounds

56
Assignee: GLAXO GROUP LTDPriority: Dec 6, 2010Filed: Dec 19, 2013Published: Apr 24, 2014
Est. expiryDec 6, 2030(~4.4 yrs left)· nominal 20-yr term from priority
Inventors:Yun JinZehong WanQing Zhang
A61P 9/10A61P 43/00A61P 25/28C07D 403/14C07D 401/14C07D 401/06C07D 413/06C07D 239/56C07D 239/52C07D 403/06C07D 401/12C07D 239/22A61K 31/506C07D 239/36C07D 239/47A61K 31/505C07D 403/12C07D 417/06
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of the formula 
       
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition comprising a compound of the formula 
       
         
           
           
               
               
           
         
       
       and one or more pharmaceutically acceptable excipients. 
     
     
         3 . The pharmaceutical composition of  claim 2  in a unit dosage form. 
     
     
         4 . A pharmaceutically acceptable salt of a compound of the formula 
       
         
           
           
               
               
           
         
       
     
     
         5 . A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of the formula 
       
         
           
           
               
               
           
         
       
       and one or more pharmaceutically acceptable excipients. 
     
     
         6 . The pharmaceutical composition of  claim 5  in a unit dosage form.

Join the waitlist — get patent alerts

Track US2014113922A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.